Announcements - OBI Pharma 台灣浩鼎

2024.Mar.11

Announcement of not Distributing Dividends in 2023

2024.Mar.11

OBI announces the termination of OBI-3424-001 trial while continuing the collaboration of OBI-3424 with partners

2024.Feb.29

Announcement on behalf of OBIGEN that it has filed the application of Phase II human clinical trial for OBI-858 to TFDA

2024.Jan.31

Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial

2024.Jan.03

OBI-992 TROP2 ADC has been granted by US FDA to proceed to Phase I/II human clinical trial

2023.Dec.29

Announcement on behalf of Amaran that its institutional director changes its representative

2023.Dec.29

The Company’s Board of Directors nominated Dr. Kung-Yee Liang to serve as the Chairperson of the Board

2023.Dec.29

Announcement on behalf of OBIGEN that its institutional director changes its representative

2023.Dec.21

Announcement that the institutional director of OBI, Sheng Cheng Investment Co., Ltd., changes its representative

2023.Dec.20

Announcement of the resignation of natural-person director

News

Latest News

Events

Latest events